Arcturus Therapeutics Holdings Inc. - Common stock, par value $0.001 per share (ARCT)

CUSIP: 03969T109

Q4 2022 13F Holders as of 31 Dec 2022

Holder snapshot 7 signals
Share change
+622,215
Put/Call ratio
45%
SEC-reported price per share
$16.96
Number of holders
111
Value change
+$11,521,684
Number of buys
55
Open additional details 1 more signal available
Number of sells
50
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
28,628,932

Security key

03969T109

Report period

Q4 2022

Institutions

111

Top holders

10

Ownership snapshot

Top reported holders of ARCT - Arcturus Therapeutics Holdings Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FEDERATED HERMES, INC.
Disclosed value leader
FEDERATED HERMES, INC.
Comparable rows
0/15
Latest evidence
30 Sep 2022
13F 3/4/5 Highest disclosed value: $52,870,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

FEDERATED HERMES, INC. has the largest disclosed position value at $52.87M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FEDERATED HERMES, INC.'s linked filing trail.
Disclosed position value Top 5
FEDERATED HERMES, INC. $52.87M
STATE STREET CORP $40.46M
ARK Investment Management LLC $32.33M
BlackRock Finance, Inc. $29.06M
Ultragenyx Pharmaceutical Inc. $26.21M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FEDERATED HERMES, INC.
13F
Company
13F
—
denominator unverified
$52,870,000
3,567,497 shares
— 30 Sep 2022
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$40,465,000
2,730,462 shares
— 30 Sep 2022
ARK Investment Management LLC
13F
Company
13F
—
denominator unverified
$32,333,000
2,181,703 shares
— 30 Sep 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$29,056,000
1,960,589 shares
— 30 Sep 2022
Ultragenyx Pharmaceutical Inc.
3/4/5
Director
—
denominator unverified
$26,208,420
1,400,000 shares
— 10 Aug 2021
Sumitomo Mitsui Trust Group, Inc.
13F
Company
13F
—
denominator unverified
$21,629,000
1,459,415 shares
— 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
111
Shares
22,638,074
Rows available
111
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders
106
Q4 2022 holders
111
Holder diff
5
Investor Q3 2022 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2022 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .